In the context of bladder cancer, this atypical glycosylation may modulate redox signaling or contribute to immune escape through an engagement of mannose-recognizing lectins, such as DC-SIGN or the macrophage mannose receptor [30,31]. Here, CD209 is linked to urinary bladder cancer.